Company news
Jiangsu Hengrui Pharmaceuticals Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Progress in A-share Repurchase
June 2, 2026
Announcement on Convening the Q1 2026 Performance Briefing
May 27, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 20, 2026
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
May 12, 2026
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
May 11, 2026
Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors
April 29, 2026
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
April 22, 2026
Announcement on Inclusion of Drug in Breakthrough Therapy Designation List
April 20, 2026
Announcement on Resolutions of the 1st Meeting of the 10th Board of Directors
April 16, 2026
Announcement on Completion of Unlocking the Lockup Period of Employee Stock Ownership Plan
April 3, 2026
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
March 30, 2026
Announcement on Convening the 2025 Annual Performance and Cash Dividend Briefing
March 27, 2026
Hengrui Pharma Announces Strong 2025 Annual Results
March 25, 2026
Indicative Announcement on Acceptance of Application for Drug Marketing Authorization
March 16, 2026
Announcement on Election of Employee Representative Directors for the 10th Board of Directors
March 2, 2026
Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program
February 24, 2026
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
February 10, 2026
Announcement on FDA Acceptance for Review of the Resubmitted Biologics License Application for Camrelizumab for Injection
February 2, 2026
Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
January 30, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 31, 2025
Announcement on Resolutions of the 15th Meeting of the 9th Board of Supervisors
December 28, 2025
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
November 4, 2025
Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion
October 27, 2025
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
October 21, 2025
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
October 20, 2025
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
September 24, 2025
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
September 7, 2025
Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893
September 5, 2025
Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Has Announced its Record-breaking First-half 2025 Results
August 20, 2025
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
July 29, 2025
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
July 27, 2025
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
July 22, 2025
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
July 15, 2025
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD
July 8, 2025
Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023
April 10, 2023
Decks
The 5 newest of 9 decks. Every deck is listed under its year.
- H1 2026 Earnings Presentation
Earnings · 50 slides · Aug 20, 2026
- H1 2026 Earnings Presentation
Earnings · 50 slides · August 2026
- Merger or Acquisition (May 2026)
Merger or acquisition · 10 slides · May 12, 2026
- Merger or Acquisition (May 2026)
Merger or acquisition · 10 slides · May 12, 2026
- FY2025 Earnings Presentation
Earnings · 35 slides · March 2026